Poor Outcomes Persist in Secondary AML Patients Previously Treated with Hypomethylating Agents
Key Insights
A large-scale PETHEMA (search) registry study reveals secondary AML patients previously treated with hypomethylating agents (search) face poor prognosis, with median overall survival of only 4.93 months.
Among treatment options, intensive chemotherapy and HMA therapy showed slightly better outcomes with median OS of 7.68 and 7.82 months respectively, while venetoclax-based regimens yielded 4.66 months.
Allogeneic stem cell transplantation emerged as the most promising intervention, with patients receiving transplants during first remission showing significantly improved survival outcomes.
The latest analysis from the PETHEMA (search) registry has revealed persistent challenges in treating secondary acute myeloid leukemia (search) (sAML) patients previously exposed to hypomethylating agents (search) (HMAs), highlighting a critical need for innovative therapeutic approaches.
The comprehensive study, examining 15,119 AML patients across Spain, Portugal, Chile, and Colombia, found that 24.2% had secondary AML, with the majority developing from prior myelodysplastic syndrome (search) (MDS) or related conditions. Among the study population, 84% of 479 patients had a history of MDS before progressing to sAML.
Patient Characteristics and Treatment Patterns
The study population had a median age of 70 years, with predominantly male patients (67%) and a median ECOG status of 1. Cytogenetic analysis revealed concerning patterns, with 51% of patients showing adverse cytogenetic risk factors and only 1% displaying favorable risk characteristics.
Treatment approaches varied significantly among the 450 patients with available frontline therapy data:
- 31% received intensive chemotherapy
- 19% underwent low-dose cytarabine-based regimens
- 17% participated in clinical trials
- 12% received HMA monotherapy
- 4% were treated with venetoclax-based regimens
Survival Outcomes and Prognostic Factors
The study revealed sobering survival statistics, with a median overall survival of 4.93 months across the entire patient population. Treatment-specific outcomes showed:
- Intensive chemotherapy: 7.68 months median OS
- HMA therapy: 7.82 months median OS
- Venetoclax-based regimens: 4.66 months median OS
Notably, the 9% of patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) during first remission demonstrated significantly better outcomes, with median OS not reached during the study period.
Risk Factors and Future Directions
Several adverse prognostic factors emerged from multivariate analyses:
- Age 65 or older
- ECOG score higher than 2
- Elevated white blood cell count
- Adverse-risk cytogenetics
The presence of NPM1 (search) mutation stood out as a favorable prognostic indicator, offering a potential avenue for targeted therapeutic approaches.
The findings underscore the urgent need for novel treatment strategies in this challenging patient population. Despite the availability of BCL2 (search) inhibitors and various therapeutic options, patients with HMA-exposed sAML continue to face poor outcomes regardless of treatment intensity.
The research team emphasizes that the optimal approach appears to be effective induction therapy followed by allo-HSCT when possible. However, given the limited success of current treatments, there is a pressing need to develop new therapeutic strategies and prioritize clinical trial participation for this vulnerable patient population.